Basilea News http://www.basilea.com/ Basilea News en Mon, 22 Dec 2014 07:13:59 +0100 Mon, 22 Dec 2014 07:13:59 +0100 Chameleon CMS webmaster@basila.com (Webmaster Webmaster) webmaster@basila.com (Webmaster Webmaster) <![CDATA[Basilea announces launch of antibiotic Zevtera® (ceftobiprole medocaril) in Germany]]> http://www.basilea.com/News-and-Media/Basilea-announces-launch-of-antibiotic-Zevtera-ceftobiprole-medocaril-in-Germany/59334b49-49f7-9596-c42f-93124a0d5979
  • First commercial launch
  • ]]>
    Fri, 05 Dec 2014 07:15:00 +0100 http://www.basilea.com/News-and-Media/Basilea-announces-launch-of-antibiotic-Zevtera-ceftobiprole-medocaril-in-Germany/59334b49-49f7-9596-c42f-93124a0d5979
    <![CDATA[Basilea reports that U.S. FDA sets date of Advisory Committee meeting on isavuconazole NDA for the treatment of invasive aspergillosis and mucormycosis]]> http://www.basilea.com/News-and-Media/Basilea-reports-that-U-S-FDA-sets-date-of-Advisory-Committee-meeting-on-isavuconazole-NDA-for-the-treatment-of-invasive-aspergillosis-and-mucormycosis/f85016da-f873-a081-172d-1403f4c6649a Fri, 21 Nov 2014 11:49:47 +0100 http://www.basilea.com/News-and-Media/Basilea-reports-that-U-S-FDA-sets-date-of-Advisory-Committee-meeting-on-isavuconazole-NDA-for-the-treatment-of-invasive-aspergillosis-and-mucormycosis/f85016da-f873-a081-172d-1403f4c6649a <![CDATA[Basilea's oncology drug candidate BAL101553 induces significant anti-tumor effect in treatment-refractory tumor models]]> http://www.basilea.com/News-and-Media/Basileas-oncology-drug-candidate-BAL101553-induces-significant-anti-tumor-effect-in-treatment-refractory-tumor-models/3a1c8cec-5ab8-93cb-4e8a-5e60a5876428
  • BAL101553 anti-cancer activity in treatment-refractory cancer models, alone and in combination with radiotherapy, presented at EORTC-NCI-AACR Symposium*
  • BAL101553 has anti-tumor activity when administered i.v. or orally in
    in-vivo models of human cancer refractory to taxanes and epothilones
  • Combination of BAL101553 with radiotherapy led to profound tumor growth delay
  • ]]>
    Wed, 19 Nov 2014 07:15:00 +0100 http://www.basilea.com/News-and-Media/Basileas-oncology-drug-candidate-BAL101553-induces-significant-anti-tumor-effect-in-treatment-refractory-tumor-models/3a1c8cec-5ab8-93cb-4e8a-5e60a5876428
    <![CDATA[Basilea reports granting of U.S. orphan drug designation to isavuconazole for the treatment of invasive candidiasis]]> http://www.basilea.com/News-and-Media/Basilea-reports-granting-of-U-S-orphan-drug-designation-to-isavuconazole-for-the-treatment-of-invasive-candidiasis/9e64139b-4735-c5a2-f5e7-b7e5f962b304 Mon, 03 Nov 2014 07:15:00 +0100 http://www.basilea.com/News-and-Media/Basilea-reports-granting-of-U-S-orphan-drug-designation-to-isavuconazole-for-the-treatment-of-invasive-candidiasis/9e64139b-4735-c5a2-f5e7-b7e5f962b304 <![CDATA[Basilea reports protocol amendment resulting in earlier completion of isavuconazole phase 3 invasive candidiasis study]]> http://www.basilea.com/News-and-Media/Basilea-reports-protocol-amendment-resulting-in-earlier-completion-of-isavuconazole-phase-3-invasive-candidiasis-study/3824c63d-5cc6-f661-4bca-f262e5f50bd3 Thu, 16 Oct 2014 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-reports-protocol-amendment-resulting-in-earlier-completion-of-isavuconazole-phase-3-invasive-candidiasis-study/3824c63d-5cc6-f661-4bca-f262e5f50bd3 <![CDATA[Basilea reports that further subgroup and health economic analyses of isavuconazole phase 3 studies will be presented at IDWeek conference]]> http://www.basilea.com/News-and-Media/Basilea-reports-that-further-subgroup-and-health-economic-analyses-of-isavuconazole-phase-3-studies-will-be-presented-at-IDWeek-conference/7ec164f4-9a35-15a2-7fb2-4673359fc9d6 Wed, 08 Oct 2014 19:41:35 +0200 http://www.basilea.com/News-and-Media/Basilea-reports-that-further-subgroup-and-health-economic-analyses-of-isavuconazole-phase-3-studies-will-be-presented-at-IDWeek-conference/7ec164f4-9a35-15a2-7fb2-4673359fc9d6 <![CDATA[Basilea's partner Astellas receives notification from U.S. FDA of acceptance of filing of isavuconazole NDA for the treatment of invasive aspergillosis and invasive mucormycosis]]> http://www.basilea.com/News-and-Media/Basileas-partner-Astellas-receives-notification-from-U-S-FDA-of-acceptance-of-filing-of-isavuconazole-NDA-for-the-treatment-of-invasive-aspergillosis-and-invasive-mucormycosis/90aab6a2-6fc6-039f-ce48-69a7c30ba6a1 Sat, 06 Sep 2014 14:15:00 +0200 http://www.basilea.com/News-and-Media/Basileas-partner-Astellas-receives-notification-from-U-S-FDA-of-acceptance-of-filing-of-isavuconazole-NDA-for-the-treatment-of-invasive-aspergillosis-and-invasive-mucormycosis/90aab6a2-6fc6-039f-ce48-69a7c30ba6a1 <![CDATA[Extensive data presented on Basilea's anti-infectives isavuconazole, ceftobiprole and BAL30072 at ICAAC ]]> http://www.basilea.com/News-and-Media/Extensive-data-presented-on-Basileas-anti-infectives-isavuconazole-ceftobiprole-and-BAL30072-at-ICAAC/fd484025-813a-7abf-e099-c851576126b3 Fri, 05 Sep 2014 07:15:00 +0200 http://www.basilea.com/News-and-Media/Extensive-data-presented-on-Basileas-anti-infectives-isavuconazole-ceftobiprole-and-BAL30072-at-ICAAC/fd484025-813a-7abf-e099-c851576126b3 <![CDATA[European Medicines Agency accepts Basilea's isavuconazole Marketing Authorization Application for review]]> http://www.basilea.com/News-and-Media/European-Medicines-Agency-accepts-Basileas-isavuconazole-Marketing-Authorization-Application-for-review/261f60fb-2ee1-7218-fe95-fbc152ffcd4a Thu, 21 Aug 2014 07:15:00 +0200 http://www.basilea.com/News-and-Media/European-Medicines-Agency-accepts-Basileas-isavuconazole-Marketing-Authorization-Application-for-review/261f60fb-2ee1-7218-fe95-fbc152ffcd4a <![CDATA[Basilea appoints Chief Commercial Officer]]> http://www.basilea.com/News-and-Media/Basilea-appoints-Chief-Commercial-Officer/8bd9f423-2cba-b3aa-a8e0-e34075f40d3a Mon, 18 Aug 2014 07:15:00 +0200 http://www.basilea.com/News-and-Media/Basilea-appoints-Chief-Commercial-Officer/8bd9f423-2cba-b3aa-a8e0-e34075f40d3a